PubRank

Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Clinical Trial ID NCT01485861

PubWeight™ 17.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01485861

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014 1.31
2 PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014 1.23
3 Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013 1.16
4 Targeting the RAS oncogene. Expert Opin Ther Targets 2013 1.02
5 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
6 PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br J Cancer 2015 1.00
7 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
8 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
9 Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell 2016 0.89
10 Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer 2015 0.89
11 Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014 0.86
12 Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol 2013 0.85
13 The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) 2015 0.84
14 CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015 0.84
15 Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol 2016 0.83
16 Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 2016 0.78
17 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015 0.77
18 Precision medicine for advanced prostate cancer. Curr Opin Urol 2016 0.76
19 Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol 2016 0.76
20 Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. PLoS One 2016 0.75
Next 100